Complications of HIV/HAART

• Fosamprenavir Substantially Increases HDL Cholesterol in Naive Patients (Poster H-156)
  Coverage by Edwin DeJesus, M.D.

• Decreased Bone Mineral Density Is Found Among HIV-Infected, African-American Men (Poster H-166)
  Coverage by Edwin DeJesus, M.D.

• Abacavir Hypersensitivity May Occur More Commonly in Patients During Primary HIV Infection (Poster H-168)
  Coverage by Gerald Pierone Jr., M.D.

• Patients With Baseline Renal Insufficiency Should Have Tenofovir Dose Reduced (Poster H-169)
  Coverage by Gerald Pierone Jr., M.D.

• High Prevalence of Sexual Dysfunction in HIV-Infected Women With Good CD4+ Cell Counts on HAART Found (Poster H-172)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

• Are There Gender Differences in Cancers in HIV-Infected Patients? (Poster H-1765)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

Drug Resistance

• Similar Genotypic Interpretation Algorithms and Phenotypic Cutoffs Seen With Both FTC and 3TC (Poster H-180)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

• No Rapid Selection of Resistance Is Observed When Lopinavir/Ritonavir "Monotherapy" Fails (Poster H-183)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

• Intermittent Viral Load "Blips" Largely Due to Assay Variation, Not Emerging Resistance (Slide H-1134)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

New Antiretrovirals

• The Investigational NNRTI GW695634 Is Well Tolerated in Healthy Volunteers (Poster A-23)
  Coverage by Paul E. Sax, M.D.

• Several Studies Examine Pharmacokinetics of Boosted Tipranavir (Posters A-455, A-456, A-457)
  Coverage by Edwin DeJesus, M.D.

• Study of Failed Protease Inhibitor Elucidates Process of New Drug Creation (Poster F-485)
  Coverage by Paul E. Sax, M.D.

• 10-Day Results of Small D-D4FC (Reverset) Study Suggests Activity in Treatment-Experienced, NRTI-Resistant Patients (Slide H-1130)
  Coverage by Paul E. Sax, M.D.

• Prevalence of CCR5 and CXCR4 Co-Receptor Tropism in a Large HIV-Infected Cohort (Slide H-1135)
  Coverage by Paul E. Sax, M.D.

• Tipranavir Demonstrates Efficacy and Safety in Treatment-Experienced Patients With Significant Protease Inhibitor Mutations (Slide H-1137a)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• 837140, a CCR5 Antagonist, Appears Safe and Effective in 10-Day Trial (Slide H-1137b)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

Pharmacokinetics

• Long-Term Response to FTC in Pediatric Patients Is Similar to Adult Patients (Poster H-855)
  Coverage by Paul E. Sax, M.D.

• Patient Variables Impact Nevirapine, Efavirenz Clearance Differently (Poster H-861)
  Coverage by Mark Holodniy, M.D., F.A.C.P., C.I.C.

• Generic Fixed-Dose Combination of Triomune Shows Efficacy and Tolerability Similar to Other HAART Regimens (Poster H-867)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

Treatment-Experienced Patients

• Fixed-Dose Combination of ABC/3TC (Epzicom) vs. Twice-Daily Abacavir in Antiretroviral-Experienced Patients (Poster H-558)
  Coverage by Gerald Pierone Jr., M.D.

• Enfuvirtide Use in Heavily Treatment-Experienced Patients: The Sooner, the Better (Poster H-580)
  Coverage by Edwin DeJesus, M.D.

• Enfuvirtide: Week 12 Viral Load and CD4+ Cell Count Predict 48-Week Response (Poster H-583)
  Coverage by Calvin J. Cohen, M.D., M.S.

• Can Enfuvirtide Be Once a Day? (Poster H-866)
  Coverage by Calvin J. Cohen, M.D., M.S.

Treatment-Naive Patients

• Favorable Results of Quadruple-NRTI Regimen: Trizivir Plus Tenofovir (Posters H-563, H-564)
  Coverage by Paul E. Sax, M.D.

• Rescue Options After Failure of Tenofovir and Epzicom in the 30009 Study (Poster H-567)
  Coverage by Gerald Pierone Jr., M.D.

• Comparison of Lopinavir/Ritonavir Once Daily Vs. Twice Daily (Poster H-570)
  Coverage by Paul E. Sax, M.D.

• NNRTI Versus Boosted PI for Treatment of Patients With Advanced HIV Infection: Advanz Study (Poster H-574)
  Coverage by Gerald Pierone Jr., M.D.

• Quadruple-NRTI Regimen Can Provide Efficacy Similar to a 2-Class, Triple-Drug Regimen in Treatment-Naive Patients (Poster H-1131)
  Coverage by Margaret Hoffman-Terry, M.D., F.A.C.P.

• Tenofovir Beats AZT in Safety and Likelihood of Success (Slide H-1137c)
  Coverage by Calvin J. Cohen, M.D., M.S.

Treatment Switching/Simplification

• New Research Provides Reassurance of FTC Safety, Efficacy (Posters H-559, H-560)
  Coverage by Edwin DeJesus, M.D.

• Switch From Protease Inhibitors to Either Trizivir or Combivir and Nevirapine (Poster H-562)
  Coverage by Gerald Pierone Jr., M.D.